HGH fragment 176-191: the fat-loss end of the molecule, and the number nobody sourced

A short piece of the growth hormone molecule, marketed almost entirely on one statistic. The mechanism is real and the statistic is not what people think it is — and the difference between those two sentences is most of what is worth knowing here.

What the fragment is

Human growth hormone is 191 amino acids. Animal-only or theoretical Work in the 1990s identified the C-terminal region as carrying the lipolytic activity independently of the rest of the molecule, and fragment 176-191 is that region synthesised on its own. The claim that follows is appealing: fat metabolism without the growth-promoting and insulin-desensitising effects that come with whole growth hormone, because the fragment does not bind the growth hormone receptor and does not raise IGF-1.

That last part is testable and is the one genuinely useful monitoring instruction in the app’s entry: IGF-1 should not move. If it does, the vial contains something other than what the label says. For a compound with no reference standard and no approved product, a marker that detects mislabelling is worth more than a marker of effect.

The app models the half-life at about thirty minutes and flags it as an estimate. That is why the dosing rows describe one to two injections daily rather than a single dose, and like every estimated figure here, anything derived from it inherits the uncertainty.

The 12.5-times figure

Animal-only or theoretical Nearly every description of this peptide reports that it is 12.5 times more potent than growth hormone for fat burning. The app’s own entry repeats it. It traces back to animal work — obese rodent models comparing the fragment against whole growth hormone on lipolytic endpoints — and not to any human study. It is a real finding about mice, presented for two decades as though it were a fact about people.

What exists in humans is much thinner: no published randomised controlled trial of this fragment for fat loss at all. Compare that with AOD-9604, a modified version of the same region that was taken into phase IIb trials in humans and did not separate from placebo on its primary endpoint. That is the closest thing to a human test this mechanism has had, and it is not an encouraging one.

None of that makes the mechanism wrong. It makes the confidence unwarranted, and it makes the specific number a marketing artefact rather than a result.

The local-injection row, and sourcing

The app records a row describing injection near a target fat area. Animal-only or theoretical It is reproduced above because this site publishes what the app holds, and it is worth saying plainly that the idea behind it — that injecting subcutaneously near a fat depot produces a local rather than systemic effect — has no controlled human evidence behind it. Spot reduction is one of the more thoroughly examined claims in exercise science and has not held up in other contexts.

There is no approved product. Identity, purity and concentration rest entirely with whoever made the vial, and this fragment is a case where a mislabelled product is particularly plausible: the aka field in the app’s own reference overlaps with AOD-9604’s, and the two are frequently sold under each other’s names. This site names no vendor and no testing service.

There is no meaningful bloodwork to follow here beyond the IGF-1 check described above and a fasting glucose that should stay put. Assessment is body composition over months, which means an honest record of diet and training alongside it or the result means nothing. Anything experienced while using it belongs with a clinician who knows the whole picture.

How long one dose lasts

Try other intervals on the half-life and steady-state calculator, which runs the same function against whatever cadence you type.

The dosing rows the app records

Animal-only or theoretical Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for HGH Fragment 176-191, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• IGF-1
• HbA1c and fasting glucose

Drawbacks and risks the app records

From the app’s own entry. The first item and the fourth are the load-bearing ones, and the sixth — that it does not build muscle — is a useful corrective to how it is usually sold.

• Limited human clinical data
• Not FDA approved
• Very short half-life — multiple daily injections ideal
• Results modest without diet optimization
• Sourcing and purity verification important
• Does not build muscle — purely fat metabolism

Questions people actually ask

Is the 12.5x potency figure real?

It is a real finding in animal models and it has never been demonstrated in people. Treating it as a human fact is the single most common error in writing about this compound.

Why does IGF-1 matter if the fragment does not raise it?

That is exactly why it matters. The fragment should leave IGF-1 unchanged; a rise suggests the vial contains growth hormone or something else. It is a mislabelling detector rather than an efficacy marker.

How does it compare to AOD-9604?

AOD-9604 is a modified version of the same C-terminal region and is the one that went into human trials, where it did not separate from placebo on its primary obesity endpoint. That is the closest human evidence this mechanism has.

Does injecting near the target area do anything?

No controlled human evidence supports it. The app records the practice because it is in the reference; this page reports that the idea is untested rather than endorsing it.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.